Exhibit 99.1
Contact:
Carney Duntsch Jonathan M. Nugent
GTx, Inc. Kathy Nugent, Ph.D
Investor and Media Relations Burns McClellan, Inc.
901-523-9700 212-213-0006
GTX, INC. REPORTS FOURTH QUARTER AND YEAR END 2004 FINANCIAL RESULTS
MEMPHIS, Tenn - February 16, 2005--GTx, Inc. (Nasdaq: GTXI), a biopharmaceutical
company dedicated to the discovery, development and commercialization of
therapeutics for serious men's health conditions and oncology, today reported
financial results for the fourth quarter and year ended December 31, 2004. The
net loss for the fourth quarter and year ended December 31, 2004 was $6.9
million and $22.3 million, respectively, compared with a net loss of $4.5
million and $14.2 million for the same periods in 2003. At December 31, 2004,
GTx had cash and cash equivalents of $64.5 million.
"During 2004, we exceeded our milestones and had an excellent year. We had
positive data from our Phase IIb clinical trial of ACAPODENE(R) for the
prevention of prostate cancer in high risk men and progressed our second SARM to
a Phase I clinical trial," said Mitchell Steiner, M.D., CEO of GTx. "We believe
our four promising clinical programs, along with the company's broad discovery
pipeline, create attractive long term commercial opportunities for GTx."
Revenue for the quarter and year ended December 31, 2004 was $0.3 million and
$1.9 million, respectively, and resulted from the Company's collaboration and
license agreement with Ortho Biotech Products L. P., a subsidiary of Johnson &
Johnson, for GTx's lead selective androgen receptor modulator (SARM) compound,
andarine.
Research and development expenses for the quarter and year ended December 31,
2004 were $5.3 million and $18.0 million, respectively, compared to $3.4 million
and $10.8 million during the same periods of 2003. The increase in research and
development expenditures for both periods was primarily the result of GTx's
growing investment in its lead clinical program for ACAPODENE(R) (toremifene
citrate) in an ongoing pivotal Phase III clinical trial for the treatment of
serious side effects of androgen deprivation therapy for advanced prostate
cancer and in its fourth clinical program, ostarine, which is being developed
for andropause and other chronic conditions related to aging.
General and administrative expenses for the quarter and year ended December 31,
2004 were $2.2 million and $7.2 million, respectively, compared to the $1.2
million and $3.6 million for the same periods in 2003. The increase in both
periods primarily resulted from the addition of key personnel, increased
insurance costs, and higher professional fees to support GTx's growth and
reporting obligations as a public company.
2004 CORPORATE HIGHLIGHTS
o Completed a successful initial public offering.
o Partnered GTx's first SARM, andarine, with Ortho Biotech
Products, LP, a subsidiary of Johnson & Johnson.
o Formed collaborations with three diagnostic companies,
Hybritech, diaDexus and Tessera, to develop a diagnostic
prostatic intraepithelial neoplasia (PIN) test.
o Reported positive data from the Phase IIb clinical trial of
ACAPODENE(R) for prevention of prostate cancer in high risk
men.
o Filed a Special Protocol Assessment with the FDA for its
pivotal Phase III clinical trial of ACAPODENE(R) for
prevention of prostate cancer in high risk men.
o Purchased from Orion Corporation all remaining rights to
toremifene (the active ingredient in ACAPODENE(R)) in the
U.S., including FARESTON(R) (toremifene citrate 60mg) for
metastatic breast cancer, and additional rights in all other
countries.
o Progressed GTx's second SARM compound, ostarine, to a Phase I
clinical trial.
o Added to the Russell 3000 Index and NASDAQ Biotechnology
Index.
2005 MILESTONES
o Initiated a pivotal Phase III clinical trial of ACAPODENE(R)
for the prevention of prostate cancer in high risk men.
o Complete Phase I clinical trials and initiate a Phase II
clinical trial of ostarine.
o Report interim analysis of bone mineral density from the
ongoing Phase III clinical trial of ACAPODENE(R) for the
treatment of side effects of androgen deprivation therapy for
advanced prostate cancer.
o Initiate a Phase II clinical trial of andarine with partner
Ortho Biotech Products, LP, a subsidiary of Johnson & Johnson.
2005 FINANCIAL GUIDANCE
The Company anticipates that by the end of 2005, it will have two ongoing
pivotal Phase III clinical trials and two ongoing Phase II clinical trials for a
total of four clinical programs. As a result of these programs, the Company
anticipates a net loss for 2005 of approximately $35 million to $45 million.
CONFERENCE CALL
There will be a conference call today at 10am Eastern Time to discuss GTx's
fourth quarter and full year financial results and to provide a company update.
To listen to the conference call, please dial 800-291-9234 from the United
States or Canada or 617-614-3923 from outside North America. The access code for
the call is 71909405. A playback of the call will be
available from approximately 12:00 p.m., Eastern Time today through March 2,
2005 and may be accessed by dialing 888-286-8010 from the United States or
Canada or 617-801-6888 from outside North America, and referencing reservation
number 74169468. Additionally, you may access the live and subsequently archived
webcast of the conference call from the Investor Relations section of the
Company's website at http://www.gtxinc.com.
ABOUT GTX
GTx is a biopharmaceutical company dedicated to the discovery, development and
commercialization of therapeutics primarily related to the treatment of serious
men's health conditions and oncology. GTx's drug discovery and development
programs are focused on small molecules that selectively modulate the effects of
estrogens and androgens, two essential classes of hormones. GTx has a marketed
product and four clinical programs. The marketed product is FARESTON(R)
(toremifene citrate 60mg) tablets for the treatment of metastatic breast cancer.
In two of its clinical programs, the company is developing the same active
compound, toremifene citrate, as ACAPODENE(R) for two separate indications in
men: (1) a pivotal Phase III clinical trial for the prevention of prostate
cancer in high risk men and (2) a pivotal Phase III clinical trial for the
treatment of serious side effects of androgen deprivation therapy for advanced
prostate cancer. In its third clinical program, GTx and its partner, Ortho
Biotech Products, L.P., a subsidiary of Johnson & Johnson, are developing
andarine, a SARM, which is expected to enter a Phase II clinical trial in 2005.
In its fourth clinical program, GTx is developing its second SARM, ostarine, for
andropause and other chronic conditions related to aging, including sarcopenia.
In addition, GTx has an extensive preclinical pipeline generated from its own
discovery program which includes the specific product candidates, prostarine, a
SARM for benign prostatic hyperplasia (BPH), and andromustine, an anticancer
drug, for hormone refractory prostate cancer.
FORWARD-LOOKING INFORMATION IS SUBJECT TO RISK AND UNCERTAINTY
This press release contains forward-looking statements, including, without
limitation, statements related to GTx's current and anticipated clinical trials
and its other research and development programs and the matters discussed in the
"Anticipated 2005 Milestones" and "2005 Financial Guidance" sections. These
forward-looking statements are based upon GTx's current expectations.
Forward-looking statements involve risks and uncertainties. GTx's actual results
and the timing of events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and uncertainties, which
include, without limitation, risks that GTx will need substantial additional
funding and may be unable to raise capital when needed; GTx will not be able to
achieve its milestones within the time period indicated or at all; neither GTx
nor its partner will be able to commercialize its product candidates if
preclinical studies do not produce successful results or clinical trials do not
demonstrate safety and efficacy in humans; if third parties do not manufacture
the Company's product candidates in sufficient quantities and at an acceptable
cost, clinical development and commercialization of its product candidates would
be delayed; use of third-party manufacturers may increase the risk that the
Company will not have adequate supplies of its product candidates; if third
parties on whom the Company relies do not perform as contractually required or
expected, the Company may not be able to obtain regulatory approval for or
commercialize its product candidates; the Company is dependent upon
collaborative arrangements to complete the development and commercialization of
some of its product candidates, and these collaborative arrangements may place
the development of its product candidates outside its control, may require it to
relinquish important rights or may otherwise be on terms unfavorable to the
Company; and if the Company is not able to obtain required regulatory approvals,
the Company will not be able to
commercialize its product candidates. You should not place undue reliance on
these forward-looking statements, which apply only as of the date of this press
release. The annual report filed on Form 10-K with the U.S. Securities and
Exchange Commission (the "SEC") on March 26, 2004 contains under the heading
"Additional Factors That Might Affect Future Results," a more comprehensive
description of these and other risks to which GTx is subject. GTx expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any
change in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
GTX, INC.
CONDENSED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
(UNAUDITED)
THREE MONTHS ENDED FOR THE YEAR ENDED
DECEMBER 31, DECEMBER 31,
------------------------- ------------------------
2004 2003 2004 2003
--------- --------- ---------- ---------
Collaboration revenue:
License fees $ 334 $ -- $ 1,055 $ --
Reimbursement of development costs 10 -- 812 --
--------- --------- --------- ---------
Total collaboration revenue 344 -- 1,867 --
Operating expenses:
Research and development 5,344 3,427 17,950 10,778
General and administrative 2,197 1,184 7,211 3,559
--------- --------- --------- ---------
Total operating expenses 7,541 4,611 25,161 14,337
--------- --------- --------- ---------
Loss from operations (7,197) (4,611) (23,294) (14,337)
Interest income 314 64 946 143
--------- --------- --------- ---------
Net loss (6,883) (4,547) (22,348) (14,194)
Accrued preferred stock dividends -- (1,136) (455) (3,436)
Adjustments to preferred stock redemption value -- (1,178) 17,125 (77,844)
--------- --------- --------- ---------
Net loss attributable to common stockholders $ (6,883) $ (6,861) $ (5,678) $ (95,474)
========= ========= ========= =========
Net loss per share attributable to common stockholders:
Basic $ (0.28) $ (0.89) $ (0.25) $ (12.34)
========= ========= ========= =========
Diluted $ (0.28) $ (0.89) $ (0.93) $ (12.34)
========= ========= ========= =========
Weighted average shares used in computing net loss
per share attributable to common stockholders:
Basic 24,659,564 7,735,125 22,993,221 7,735,125
========== ========= ========== =========
Diluted 24,659,564 7,735,125 24,062,271 7,735,125
========== ========= ========== =========
GTX, INC.
CONDENSED BALANCE SHEETS
(IN THOUSANDS)
DECEMBER 31, DECEMBER 31,
2004 2003
-------------- -------------
(unaudited) (1)
ASSETS
Cash and cash equivalents $ 64,528 $ 14,769
Other current assets 1,624 255
------------- -------------
Total current assets 66,152 15,024
Property and equipment, net 1,537 793
Purchased intangible assets, net 4,943 22
Other assets 450 --
Deferred initial public offering costs -- 1,471
------------- -------------
Total assets $ 73,082 $ 17,310
============= =============
LIABILITIES, CUMULATIVE REDEEMABLE CONVERTIBLE PREFERRED STOCK AND
STOCKHOLDERS' EQUITY (DEFICIT)
Accounts payable and accrued expenses $ 3,517 $ 2,249
Deferred revenue, current 1,337 --
------------- -------------
Total current liabilities 4,854 2,249
Deferred revenue 4,295 --
Capital lease obligation 24 --
Cumulative redeemable convertible preferred stock -- 165,292
Total stockholders' equity (deficit) 63,909 (150,231)
------------- -------------
Total liabilities and stockholders' equity (deficit) $ 73,082 $ 17,310
============= =============
(1) Derived from the audited financial statements included in the Company's
annual report on form 10-K for the year ended December 31, 2003.
# # #